← 返回

血液系统疾病中 EB 病毒血症的临床谱:病例系列及文献综述

英文原题:Clinical Spectrum of Epstein Barr Viremia in Hematological Disorders: Case Series and Review of Literature.

查看英文原题

Clinical Spectrum of Epstein Barr Viremia in Hematological Disorders: Case Series and Review of Literature.

PubMed 2025/01/27(内容时间) Indian J Hematol Blood Transfus Q4 · IF 0.6(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

大多数原发性EBV感染是无症状的,高达35%会发展为传染性单核细胞增多症(IM)。在初次原发性感染(PI)后,EBV可进行裂解性复制并引起继发表现,如慢性活动性EBV、自身免疫性疾病或肿瘤发生。

我们旨在强调EBV的血液学谱系并讨论其管理。这是一项回顾性病例系列,纳入五名经外周血定量聚合酶链反应(QPCR)确诊EBV感染的成人(> 20岁)。病例一为一名37岁女性,表现为延迟性PI,伴有全身性淋巴结肿大并自行缓解。病例二为复杂性PI,伴有严重鼻塞,需要使用类固醇。病例三为EBV诱导的自然杀伤/T细胞淋巴瘤,经改良SMILE方案治疗和放疗后达到完全缓解。病例四和病例五展示了异基因造血干细胞移植(alloHSCT)后EBV病毒血症的情况以及抢先治疗的作用。EBV感染可模拟淋巴瘤,所有伴有发热和淋巴结肿大的成人都应进行检测。尽管具有自限性,部分EBV PI可能需要类固醇治疗。早期EBV QPCR监测有助于判断预后和诊断。alloHSCT后EBV病毒血症需要从四周监测至12个月,尤其是在持续免疫抑制的情况下。

展开英文摘要原文

Most primary Ebstein-Barr Virus (EBV) infections are asymptomatic, with up to 35% developing infectious mononucleosis (IM). After the initial primary infection (PI), EBV can undergo lytic replication and cause secondary manifestations like chronic active EBV, autoimmune diseases, or tumorigenesis.

We aim to highlight the hematological spectrum of EBV and discuss its management. This is a retrospective case series of five adults (> 20 years) with confirmed EBV infection by quantitative polymerase chain reaction (QPCR) in peripheral blood. Case one showed a delayed PI with EBV in a 37-year-old female with generalized lymphadenopathy and spontaneous resolution. Case two was a complicated PI with severe nasal obstruction requiring steroids. Case three was EBV-induced Natural killer / T cell lymphoma with a complete response to modified SMILE therapy and radiation.

Cases four and five demonstrate post-allogeneic hematopoietic stem cell transplant (alloHSCT) scenarios of EBV viremia and role of pre-emptive therapy. EBV infection can mimic lymphomas and should be tested in all adults with fever and lymphadenopathy. Although self-limiting, some EBV PI may need steroids. Early EBV QPCR monitoring can aid in prognostication and diagnosis. Post-alloHSCT EB viremia needs monitoring from four weeks to 12 months, especially with ongoing immunosuppression.

论文信息

作者
Jain P、Khandelwal K、Jessani L、K JT、Madhav B、Singh T、Patekar P、Lokhande V
第一作者单位
Present Address: Department of Hematology Oncology and Bone Marrow Transplant Unit, Apollo Hospitals, Navi Mumbai, India.India
通讯作者单位
Department of Microbiology, Apollo Hospitals, Navi Mumbai, India.India
期刊
Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion2025 Oct
原文标识
PubMed 41084555 · DOI 10.1007/s12288-025-01959-3